Home
Viralgen

Viralgen Market Share Analysis for June 2026

Scale your innovation with help from the world leader in AAV-based gene therapy manufacturing.

Industry: N/A

Domainviralgen.com

Year Founded2017

Employees201 - 500

Annual Revenue--

Viralgen

Viralgen (including company regionals)

viralgen.com

See more website traffic and engagement information

Total visits to Viralgen's top domains

Understand Viralgen market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

viralgen.com5.6K

See more with Sales Intelligence

Avg. visit duration in Viralgen's top domains

Analyze Viralgen engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

viralgen.com00:00:36

See more with Sales Intelligence

Avg. pageviews on Viralgen's top domains

See how Viralgen keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

viralgen.com1.91

See more with Sales Intelligence

Viralgen top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Viralgen

These are the website technologies, by industry, used by Viralgen top domains

Social (4)

Instagram

Payment & Currencies (3)

Visa

Advertising (2)

TikTok Pixel

Content Management System (2)

WordPress

More Technologies

9

See all

News & Signals from Viralgen

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsViralgen Vector Core partnered with Elaaj Bio on May 5th '26.SAN SEBASTIÁN, Spain and LONDON, May 5, 2026 /PRNewswire/ - Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development of transformative treatments for CDKL5 Deficiency Disorder (CDD).

NewsApertura Gene Therapy, LLC partnered with Viralgen Vector Core on Jan 1st '26.We expect to see multiple Apertura partners advance programs using TfR1 CapX into the clinic this year and next, and this collaboration with Viralgen is designed to facilitate the advancement of novel therapies leveraging TfR1 CapX," said Diego Garzón, Ph.D., Chief Business Officer at Apertura.

NewsViralgen Vector Core partnered with Trogenix Ltd on May 6th '25.SAN SEBASTIÁN, May 6, 2025 /PRNewswire/ - Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, has established a strategic collaboration with Trogenix, a pioneering biotech company dedicated to developing innovative cancer therapies.